


## NDEWS Special Report EMS encounters for xylazine- and medetomidine-related overdoses (nonfatal and fatal) in the US January 1, 2023 - March 31, 2025

In this week's report, NDEWS highlights observations from biospatial.io detailing the EMS encounters for xylazine- and medetomidine-related overdoses in the US from Q1 2023 to Q1 2025. **The data shows that counties were located throughout eastern region of the US.** Among states with at least 75% coverage, there were 1,233 EMS encounters.

### US counties with the highest EMS encounters for xylazine- and medetomidine-related overdoses (nonfatal and fatal) January 1, 2023 - March 31, 2025



## US counties with the highest EMS encounters for xylazine- and medetomidine-related overdoses (nonfatal and fatal) January 1, 2023 - March 31, 2025

County*	Total EMS encounters**		Q1 2023		Q2 2023		Q3 2023		Q4 2023		Q1 2024		Q2 2024		Q3 2024		Q4 2024		Q1 2025	
	X	M	X	M	X	M	X	M	X	M	X	M	X	M	X	M	X	M	X	M
Philadelphia, PA	85	20	0	S	S	0	S	0	11	0	11	0	15	0	15	S	17	S	17	11
Allegheny, PA	53	0	0	0	S	0	S	0	0	0	S	0	S	0	10	0	S	0	19	0
Polk, FL	0	16	0	0	0	0	0	S	0	S	0	S	0	S	0	S	0	0	0	0
Delaware, PA	36	0	0	0	S	0	S	0	S	0	S	0	S	0	S	0	S	0	S	0
Montgomery, PA	27	0	0	0	S	0	S	0	S	0	S	0	S	0	S	0	S	0	S	0
Gaston, NC	24	0	0	0	S	0	S	0	S	0	S	0	S	0	S	0	S	0	0	0
Wake, NC	15	0	S	0	0	0	0	0	0	0	S	0	S	0	S	0	0	0	S	0
Onondaga, NY	12	0	0	0	0	0	0	0	S	0	S	0	S	0	0	0	S	0	S	0
Lehigh, PA	11	0	0	0	0	0	S	0	S	0	0	0	S	0	S	0	S	0	S	0
Bucks, PA	11	0	0	0	0	0	0	0	S	0	S	0	S	0	S	0	S	0	S	0
Lexington, SC	10	0	0	0	S	0	S	0	S	0	0	0	0	0	0	0	0	0	S	0

X=Xylazine-related EMS encounters

M=Medetomidine-related EMS encounters

S=EMS encounters less than ten are suppressed

\*Note: EMS encounters reflect state clustering

\*\*Limitations: Biospatial.io focuses on pre-hospital data, so it does not indicate hospital outcomes, toxicology confirmation, medical history or prescription data. The total EMS encounters are not reflected in the table because quarters that have less than ten encounters are suppressed. These limitations should be considered when interpreting the findings.

**Xylazine-related EMS encounters** were included if the Narrative/Patient Complaint contained "xylazine" or "tranq"

**Medetomidine-related EMS encounters** were included if the Chief complaint/Narrative in the Narrative Text Search contained "medetomidine", "dexmedetomidine" or "precedex"

All dispatch types above follow the guidelines set by the National Emergency Medical Services Information System (NEMSIS). Data is limited to 28 US states/districts with statewide partnerships with biospatial.io: Alabama, Alaska, Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Kansas, Kentucky, Maine, Michigan, Minnesota, Mississippi, Montana, New Mexico, New York, North Carolina, Pennsylvania, Rhode Island, South Carolina, Tennessee, Utah, Virginia, Wisconsin, and Wyoming.

States included in this report met or exceeded a 75% coverage during the surveillance period, indicating that biospatial.io has received at least 75% of the expected data for the given time and region.